737 results on '"Sacco, Rodolfo"'
Search Results
2. Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib
3. Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care
4. Codification and the Interpreter
5. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments
6. Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments
7. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis
8. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs
9. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
10. Codification and the Interpreter
11. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma
12. Bright Luminal Sign on High b-Value Diffusion-Weighted Magnetic Resonance Enterography Imaging as a New Biomarker to Predict Fibrotic Strictures in Crohn's Disease Patients: A Retrospective Preliminary Study.
13. Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis
14. LBP-038 Expanding knowledge regarding real-world treatment of patients with primary biliary cholangitis with obeticholic acid from the Italian RECAPITULATE cohort
15. THU-093 Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid
16. Development and validation of a scoring system to predict response to obeticholic acid in primary biliary cholangitis.
17. Efficacy of hemostatic powders in lower gastrointestinal bleeding: Clinical series and literature review
18. Utilization of Hepatocellular Carcinoma Surveillance Programs in Patients With Cirrhosis: A Systematic Review and Meta-Analysis
19. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.
20. Real-world experience with obeticholic acid in patients with primary biliary cholangitis
21. Repeated Previous Transarterial Treatments Negatively Affect Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib.
22. Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy
23. Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments
24. General Editors’ Preface
25. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis
26. Le passé, le présent et le futur du droit comparé
27. Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
28. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs
29. The History and Importance of Comparative Law in Italy
30. Diversity and Uniformity in the Law
31. Needle-based confocal laser endomicroscopy in pancreatic cysts: a meta-analysis
32. Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group
33. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation
34. Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
35. Cholangiocarcinoma in the Era of Immunotherapy
36. Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma
37. Predicting cardiovascular risk in patients with HCC receiving tyrosine kinase inhibitors: comparison of two different scores
38. Long-term real-world experience with obeticholic acid in primary biliary cholangitis: the Italian recapitulate study
39. Development and validation of a score predicting response to obeticholic acid in primary biliary cholangitis: the OCA response score (ORS)
40. Efficacy and safety of lusutrombopag in a real-world Italian series of cirrhotic patients with severe thrombocytopenia undergoing invasive procedures: the Reality study
41. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study
42. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study
43. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study
44. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
45. Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
46. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma
47. Remerciements/Acknowledgements
48. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study
49. Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma
50. Understanding the Drawbacks of the Current Tumor Staging Systems: How to Improve?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.